High-risk thyroid cancer. Prolonged survival with early multimodality therapy

Area of Science:

• Oncology
• Thyroid Cancer Research

Background:

• High-risk thyroid carcinoma, particularly anaplastic or mixed anaplastic-differentiated histology, presents a significant treatment challenge.
• The EORTC prognostic index aids in classifying patients for risk-stratified treatment.

Purpose of the Study:

• To evaluate an early multimodality treatment approach for high-risk thyroid carcinoma.
• To assess the efficacy and tolerability of a combined chemotherapy, radioiodine, and immunotherapy regimen.

Main Methods:

• Eleven patients with high-risk thyroid carcinoma received a four-drug chemotherapy combination, radioiodine (131I), and Bacille-Calmette-Guerin (BCG) immunotherapy.
• Treatment was tailored to target both anaplastic and differentiated tumor components.

Main Results:

• Prolonged disease-free survival (14+ to 73+ months) was observed in patients with clear cell, small cell, and mixed anaplastic histologies.
• Five patients achieved complete remission, sustained for over 4 years.
• The multimodality treatment was generally well-tolerated.

Conclusions:

• An early multimodality approach combining chemotherapy, radioiodine, and BCG immunotherapy shows promising results for high-risk thyroid carcinoma.
• This strategy offers a potential basis for future multicenter trials to further validate its efficacy.